604 related articles for article (PubMed ID: 33672138)
1. HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies.
Khanal S; Schank M; El Gazzar M; Moorman JP; Yao ZQ
Cells; 2021 Feb; 10(2):. PubMed ID: 33672138
[TBL] [Abstract][Full Text] [Related]
2. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
3. Modeling HIV-1 Latency Using Primary CD4
Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
[TBL] [Abstract][Full Text] [Related]
4. Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.
Sadowski I; Hashemi FB
Cell Mol Life Sci; 2019 Sep; 76(18):3583-3600. PubMed ID: 31129856
[TBL] [Abstract][Full Text] [Related]
5. Selective BCL-X
Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of latently infected HIV-1 viral reservoirs and correction of aberrant alternative splicing in the LMNA gene via AMPK activation: Common mechanism of action linking HIV-1 latency and Hutchinson-Gilford progeria syndrome.
Finley J
Med Hypotheses; 2015 Sep; 85(3):320-32. PubMed ID: 26115946
[TBL] [Abstract][Full Text] [Related]
7. Breaking the Silence: Regulation of HIV Transcription and Latency on the Road to a Cure.
Duggan NN; Dragic T; Chanda SK; Pache L
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140676
[TBL] [Abstract][Full Text] [Related]
8. Brain Macrophages in Simian Immunodeficiency Virus-Infected, Antiretroviral-Suppressed Macaques: a Functional Latent Reservoir.
Avalos CR; Abreu CM; Queen SE; Li M; Price S; Shirk EN; Engle EL; Forsyth E; Bullock BT; Mac Gabhann F; Wietgrefe SW; Haase AT; Zink MC; Mankowski JL; Clements JE; Gama L
mBio; 2017 Aug; 8(4):. PubMed ID: 28811349
[TBL] [Abstract][Full Text] [Related]
9. VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies.
Puertas MC; Bayón-Gil Á; Garcia-Guerrero MC; Salgado M; Urrea V; Morón-López S; Peña R; Jiménez-Moyano E; Clotet B; Prado JG; Martinez-Picado J
mBio; 2021 Jun; 12(3):e0056021. PubMed ID: 34154408
[TBL] [Abstract][Full Text] [Related]
10. Reduce and Control: A Combinatorial Strategy for Achieving Sustained HIV Remissions in the Absence of Antiretroviral Therapy.
Schwarzer R; Gramatica A; Greene WC
Viruses; 2020 Feb; 12(2):. PubMed ID: 32046251
[TBL] [Abstract][Full Text] [Related]
11. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
12. Barriers for HIV Cure: The Latent Reservoir.
Castro-Gonzalez S; Colomer-Lluch M; Serra-Moreno R
AIDS Res Hum Retroviruses; 2018 Sep; 34(9):739-759. PubMed ID: 30056745
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Latency and Eradication: Past, Present and Future.
Datta PK; Kaminski R; Hu W; Pirrone V; Sullivan NT; Nonnemacher MR; Dampier W; Wigdahl B; Khalili K
Curr HIV Res; 2016; 14(5):431-441. PubMed ID: 27009094
[TBL] [Abstract][Full Text] [Related]
14. Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.
Siliciano JD; Siliciano RF
J Infect Dis; 2021 Feb; 223(12 Suppl 2):13-21. PubMed ID: 33586775
[TBL] [Abstract][Full Text] [Related]
15. The Current Status of Latency Reversing Agents for HIV-1 Remission.
Rodari A; Darcis G; Van Lint CM
Annu Rev Virol; 2021 Sep; 8(1):491-514. PubMed ID: 34586875
[TBL] [Abstract][Full Text] [Related]
16. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
17. TLR1/2 Agonist Enhances Reversal of HIV-1 Latency and Promotes NK Cell-Induced Suppression of HIV-1-Infected Autologous CD4
Duan S; Xu X; Wang J; Huang L; Peng J; Yu T; Zhou Y; Cheng K; Liu S
J Virol; 2021 Aug; 95(17):e0081621. PubMed ID: 34133900
[TBL] [Abstract][Full Text] [Related]
18. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages.
Hany L; Turmel MO; Barat C; Ouellet M; Tremblay MJ
J Virol; 2022 Feb; 96(4):e0195321. PubMed ID: 34878918
[TBL] [Abstract][Full Text] [Related]
19. A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs.
Lassen KG; Hebbeler AM; Bhattacharyya D; Lobritz MA; Greene WC
PLoS One; 2012; 7(1):e30176. PubMed ID: 22291913
[TBL] [Abstract][Full Text] [Related]
20. Irreversible Loss of HIV-1 Proviral Competence in Myeloid Cells upon Suppression of NF-κB Activity.
Peters RJ; Stevenson M
J Virol; 2022 Jun; 96(12):e0048422. PubMed ID: 35604217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
